INSIGHT. In the pharmaceutical industry, contract development and manufacturing organizations (CDMOs) have taken on an increasingly central role. Over the past decade, these companies have shifted from being mere manufacturing partners to becoming drivers of innovation and technological development.
To meet the changing demands of the pharmaceutical industry and the growing need for new therapies and pharmaceuticals, many CDMOs have started adapting their business models. Between 2017 and 2021, more than 240 global M&A transactions took place in the sector, with one-third involving new modalities such as cell and gene therapies.
Through strategic acquisitions and investments in new technologies, CDMOs have been able to offer more advanced manufacturing services and have expanded to cover the entire value chain, from preclinical research to commercial launch. By embracing digitalisation and automation, they have further strengthened their leadership in improving efficiency and quality in drug production. This development has established CDMOs as key players in the industry, and their influence is expected to continue growing over the next decade.
Receive news and invitations from Sciety
Join our newsletter to be the first to know about new investment opportunities and receive invitations to company presentations, seminars, and events.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.
Latest news
